On November 24, 2025, Alvotech announced that the European Commission (EC) has approved AVT03 as a biosimilar to Amgen’s PROLIA® and ...

Our news journalists obtained a quote from the research from Optum, "Potential denosumab 60 mg off-label use was observed based on claims, but many had evidence of on-label indications based on ...

REYKJAVIK, ICELAND (September 22, 2024) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today ...

Basel: Sandoz has announced the European launch of Wyost (denosumab 120 mg) and Jubbonti (denosumab 60 mg). The medicines are ...

Alvotech (ALVO) on Monday said that the European Commission has approved AVT03 as a biosimilar to Prolia and Xgeva (denosumab ...

OBODENCE (60 mg pre-filled syringe) and XBRYK (120 mg vial) become available across Europe as of December 2025 and January 2026, respectively Marks Samsung Bioepis' 10th and 11th biosimilars ...

Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) approved a new indication for Prolia® (denosumab) as a treatment to increase bone mass in men with osteoporosis at high ...

Please provide your email address to receive an email when new articles are posted on . Denosumab is a monoclonal antibody inhibitor of receptor activator of nuclear factor kappa B ligand that ...

AVT03 is approved in two presentations: as a biosimilar to Prolia ® 60 mg/mL single use pre-filled syringe for the treatment of osteoporosis and bone loss; and as a biosimilar to Xgeva ® 70 mg/mL ...

Researchers published the study covered in this summary on researchsquare.com as a preprint that has not yet been peer reviewed. Study participants had no clinical fractures during 24 months of follow ...

Samsung Bioepis Co., Ltd. today announced the launch of OBODENCE™ (60 mg pre-filled syringe) and XBRYK™ (120 mg vial), ...